Fig. 6

The novel marker can predict acute rejection in a validation cohort. Comparison of the percentages of IFN-γ⁺CD4⁺T cells and GrB⁺CD19⁺B cells between liver transplant recipients with and without acute rejection (a, b); Correlations of the percentages of IFN-γ⁺CD4⁺T cells and the percentages of GrB⁺CD19⁺B cells (c); Comparison of the novel marker between liver transplant recipients with and without acute rejection (d); ROC curve analysis of the percentages of IFN-γ⁺CD4⁺T cells and GrB⁺CD19⁺B cells and the novel marker (e); The occurrence rate of acute rejection between liver transplant recipients with new marker > 62.93% and < 62.93% (f). Bars represent mean and standard deviation. GrB granzyme B, ROC receiver operating characteristic, AUC area under the curve